NEW YORK (GenomeWeb News) – Med BioGene today reported no revenues for the first quarter, the same as in the first quarter of 2012.

For the three months ended March 31, the Vancouver, British Columbia-based molecular diagnostics firm said the comprehensive loss totaled $74,133, or breakeven, compared to a loss of $120,701, or breakeven, a year ago, according to a document filed with Canadian regulators.

SG&A costs were lowered 35 percent to $78,414 from $121,296.

Med BioGene reported $291,717 in cash and cash equivalents at the end of the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.